AC Immune S.A. (ACIU)

$3.99 +0.86 (27.48%)
Market Cap 314.28M
Revenue (ttm) 31.02M
Net Income (ttm) -57.84M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -186.46%
Debt to Equity Ratio 0.00
Volume 1,072,900
Avg Vol 166,638
Day's Range N/A - N/A
Shares Out 100.41M
Stochastic %K 100%
Beta 1.56
Analysts Strong Sell
Price Target $9.00

Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It develops Crenezumab, a humanized, confor...

Industry: Biotechnology
Sector: Healthcare
Phone: 41 21 345 91 21
Fax: 41 21 345 91 20
Address:
Building B, EPFL Innovation Park, Lausanne, Switzerland
Vikingsstrade
Vikingsstrade Oct. 4 at 6:05 PM
$GROY $AZO $PHM $ACIU Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
highnihilism
highnihilism Oct. 4 at 4:22 PM
$ACIU AC Immune volume 1,041,910 | average 138,603 × 7.5 | price 3.99 +0.86 (+27.5%) earnings 08-05-25 bmo
0 · Reply
StockScanners
StockScanners Oct. 4 at 2:40 PM
$ACIU keep watch if this holds above 3.70
0 · Reply
lucabrix
lucabrix Oct. 3 at 7:24 PM
$ACIU Reply!!
1 · Reply
ChazzyTrades
ChazzyTrades Oct. 3 at 6:07 PM
$ACIU ez money
0 · Reply
GoldenBridgeCapital
GoldenBridgeCapital Oct. 3 at 5:00 PM
$ACIU This is a pullback, not a pullout 😂 bulls still heavy, price still tight, structure still valid.
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:37 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $SRPT $SPCE $ACIU $QBTS
0 · Reply
wyoming2020
wyoming2020 Oct. 3 at 3:34 PM
$ACIU my goodness
0 · Reply
BLD33
BLD33 Oct. 3 at 2:48 PM
$ACIU next boom $LAC wrote about perfect buy at pullback!!!
0 · Reply
DaBullRunner
DaBullRunner Oct. 3 at 2:06 PM
$ACIU there it goes…. DTCK is going to make a big run soon on that news 🚨 $1+ coming I’m telling you 🎯✅ WATCH AND LEARN LIKE HIM👇
0 · Reply
Latest News on ACIU
AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Aug 5, 2025, 7:00 AM EDT - 2 months ago

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 30, 2025, 7:00 AM EDT - 5 months ago

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

Apr 2, 2025, 6:00 AM EDT - 6 months ago

AC Immune Reports Further Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson's Disease

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

Mar 25, 2025, 7:00 AM EDT - 6 months ago

AC Immune Announces Upcoming Presentations and Industry Symposium on Active Immunotherapies at AD/PD™ 2025

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

Mar 13, 2025, 7:00 AM EDT - 7 months ago

AC Immune Reports Full Year 2024 Financial Results and Provides a Corporate Update

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

Nov 14, 2024, 10:32 AM EST - 11 months ago

AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

Jul 31, 2024, 8:30 AM EDT - 1 year ago

AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

Jul 26, 2024, 3:10 PM EDT - 1 year ago

AC Immune: Takeda Partnership Brings Funds To Drive Pipeline Forward

AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease

Jul 25, 2024, 7:00 AM EDT - 1 year ago

AC Immune's ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer's Disease

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

May 28, 2024, 7:00 AM EDT - 1 year ago

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

Alzheimer's vaccine licensing deal boosts AC Immune

May 13, 2024, 8:47 AM EDT - 1 year ago

Alzheimer's vaccine licensing deal boosts AC Immune

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

May 13, 2024, 6:05 AM EDT - 1 year ago

AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

May 13, 2024, 6:00 AM EDT - 1 year ago

AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer's Disease

TAK

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

Mar 14, 2024, 7:00 AM EDT - 1 year ago

AC Immune Reports Full Year 2023 Financial Results and Provides a Corporate Update

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

Feb 22, 2024, 7:00 AM EST - 1 year ago

AC Immune Announces Upcoming Presentations at AD/PD™ 2024

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

Jan 22, 2024, 7:00 AM EST - 1 year ago

AC Immune to Regain Global Rights to Crenezumab and Semorinemab

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

Jan 3, 2024, 8:10 AM EST - 1 year ago

AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer's and Parkinson diseases

AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts

Dec 18, 2023, 6:25 PM EST - 1 year ago

AC Immune: Initial AD Findings Bring About Two Upcoming Catalysts

AC Immune Announces Pricing of Underwritten Offering of Common Shares

Dec 15, 2023, 7:56 AM EST - 1 year ago

AC Immune Announces Pricing of Underwritten Offering of Common Shares

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

Dec 15, 2023, 7:22 AM EST - 1 year ago

AC Immune's Targeted Anti-pTau Active Immunotherapy for Alzheimer's Disease Advances into Phase 2b Trial

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

Dec 1, 2023, 7:00 AM EST - 2 years ago

AC Immune Strengthens Management, Appoints Madiha Derouazi as CSO and Christopher Roberts as CFO

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

Nov 7, 2023, 7:00 AM EST - 2 years ago

AC Immune to Present at the Jefferies 2023 London Healthcare Conference

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

Nov 3, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

Nov 2, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer's Disease as a Surrogate of Clinical Efficacy on November 9, 2023

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

Oct 27, 2023, 7:00 AM EDT - 2 years ago

AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

Oct 17, 2023, 7:00 AM EDT - 2 years ago

AC Immune Announces Upcoming Presentations at the 16th CTAD Conference

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

Oct 5, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the Jefferies 2023 CNS & Neuro Summit in October 2023

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

Sep 5, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the H.C. Wainwright 25th Annual Global Investment Conference in September 2023

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

Aug 4, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

Jul 28, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Present at the BTIG Virtual Biotechnology Conference 2023

AC Immune SA Appoints New Chief Medical Officer

Jul 26, 2023, 7:00 AM EDT - 2 years ago

AC Immune SA Appoints New Chief Medical Officer

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

Jul 3, 2023, 7:00 AM EDT - 2 years ago

AC Immune Showcasing Precision Medicine Programs at AAIC 2023

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

Jun 27, 2023, 7:52 AM EDT - 2 years ago

AC Immune's stock soars 13% after FDA grants fast-track designation to Alzheimer's treatment

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

Jun 27, 2023, 7:00 AM EDT - 2 years ago

AC Immune Receives FDA Fast Track Designation for Anti-Amyloid-beta Active Immunotherapy, ACI-24.060, to Treat Alzheimer's Disease

AC Immune Holds Annual General Meeting of Shareholders

Jun 23, 2023, 4:30 PM EDT - 2 years ago

AC Immune Holds Annual General Meeting of Shareholders

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

Apr 28, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports First Quarter 2023 Financial Results and Provides a Corporate Update

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

Apr 5, 2023, 7:00 AM EDT - 2 years ago

AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer's Disease

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

Mar 20, 2023, 8:00 AM EDT - 2 years ago

AC Immune at AD/PD™ 2023 to Present New Clinical and Preclinical Data from its Precision Medicine Pipeline

AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures

Mar 18, 2023, 9:00 AM EDT - 2 years ago

AC Immune: Dementia-Focused Swiss Biotech With A Sad History Of Failures

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

Mar 16, 2023, 7:00 AM EDT - 2 years ago

AC Immune Reports Full Year 2022 Financial Results and Provides Corporate Update

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

Mar 8, 2023, 7:00 AM EST - 2 years ago

AC Immune to Report Full Year 2022 Financial Results and Provide Corporate Update on March 16, 2023

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

Feb 7, 2023, 7:00 AM EST - 2 years ago

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43

AC Immune to Present at the SVB Securities Global Biopharma Conference

Feb 2, 2023, 8:15 AM EST - 2 years ago

AC Immune to Present at the SVB Securities Global Biopharma Conference

AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

Jan 26, 2023, 7:00 AM EST - 2 years ago

AC Immune's ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer's Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease

Jan 18, 2023, 7:00 AM EST - 2 years ago

AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer's Disease

Why I've Added A Full Position In AC Immune To My Tax Loss Selling Basket

Dec 27, 2022, 1:02 PM EST - 3 years ago

Why I've Added A Full Position In AC Immune To My Tax Loss Selling Basket

AC Immune's Alzheimer's Disease Vaccine-candidate ACI-35.030 Selected for Further Development

Nov 30, 2022, 7:00 AM EST - 3 years ago

AC Immune's Alzheimer's Disease Vaccine-candidate ACI-35.030 Selected for Further Development

AC Immune to Present Progress of Alzheimer's Disease Programs targeting Abeta and Tau at the 15th CTAD Conference

Nov 23, 2022, 7:30 AM EST - 3 years ago

AC Immune to Present Progress of Alzheimer's Disease Programs targeting Abeta and Tau at the 15th CTAD Conference

AC Immune to Present at the Jefferies London Healthcare Conference

Nov 8, 2022, 7:58 AM EST - 3 years ago

AC Immune to Present at the Jefferies London Healthcare Conference

AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Oct 28, 2022, 8:00 AM EDT - 3 years ago

AC Immune Reports Third Quarter 2022 Financial Results and Provides a Corporate Update

Vikingsstrade
Vikingsstrade Oct. 4 at 6:05 PM
$GROY $AZO $PHM $ACIU Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve!
0 · Reply
highnihilism
highnihilism Oct. 4 at 4:22 PM
$ACIU AC Immune volume 1,041,910 | average 138,603 × 7.5 | price 3.99 +0.86 (+27.5%) earnings 08-05-25 bmo
0 · Reply
StockScanners
StockScanners Oct. 4 at 2:40 PM
$ACIU keep watch if this holds above 3.70
0 · Reply
lucabrix
lucabrix Oct. 3 at 7:24 PM
$ACIU Reply!!
1 · Reply
ChazzyTrades
ChazzyTrades Oct. 3 at 6:07 PM
$ACIU ez money
0 · Reply
GoldenBridgeCapital
GoldenBridgeCapital Oct. 3 at 5:00 PM
$ACIU This is a pullback, not a pullout 😂 bulls still heavy, price still tight, structure still valid.
0 · Reply
Vikingsstrade
Vikingsstrade Oct. 3 at 4:37 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $SRPT $SPCE $ACIU $QBTS
0 · Reply
wyoming2020
wyoming2020 Oct. 3 at 3:34 PM
$ACIU my goodness
0 · Reply
BLD33
BLD33 Oct. 3 at 2:48 PM
$ACIU next boom $LAC wrote about perfect buy at pullback!!!
0 · Reply
DaBullRunner
DaBullRunner Oct. 3 at 2:06 PM
$ACIU there it goes…. DTCK is going to make a big run soon on that news 🚨 $1+ coming I’m telling you 🎯✅ WATCH AND LEARN LIKE HIM👇
0 · Reply
buyslowsellfast
buyslowsellfast Oct. 3 at 2:05 PM
Sold some $ACIU 3.39. Bought shares on sale in March.
0 · Reply
lucabrix
lucabrix Oct. 2 at 3:00 PM
$ACIU here we go!!!
0 · Reply
highnihilism
highnihilism Oct. 1 at 10:43 AM
$NVST Envista Trades: 7 | Total $: 1.3 K | 90D Avg: 17.7 K | Rel. Notional: 0.07 | Call $: 1.3 K | Put $: 48 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $ACIU AC Immune Trades: 4 | Total $: 1.3 K | 90D Avg: 1.8 K | Rel. Notional: 0.72 | Call $: 1.3 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $VRE Veris Residential Trades: 1 | Total $: 1.3 K | 90D Avg: 5.2 K | Rel. Notional: 0.24 | Call $: 1.3 K | Put $: 0 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: – $IWD iShares Russell 1000 Value ETF Trades: 2 | Total $: 1.9 K | 90D Avg: 370.2 K | Rel. Notional: 0.01 | Call $: 1.3 K | Put $: 600 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
midas7576
midas7576 Sep. 30 at 6:41 AM
$ACIU https://pharmatimes.com/news/ac-immunes-tau-targeting-therapy-shows-promise-in-early-alzheimers-trial/
0 · Reply
ShadowyForeignExchange
ShadowyForeignExchange Sep. 30 at 12:34 AM
$ACIU it’s coming
0 · Reply
lucabrix
lucabrix Sep. 29 at 7:16 PM
$ACIU here we go, pass 3$ and run
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 29 at 5:49 AM
$ACIU Excellent article that nails exactly where ACIU stands right now. So if you want to update your ACIU knowledge or get acquainted with ACIU, this is a must read. https://beyondspx.com/quote/ACIU/analysis/ac-immune-s-focused-innovation-a-sharpened-path-in-neurodegeneration-nasdaq-aciu
0 · Reply
wyoming2020
wyoming2020 Sep. 26 at 1:27 PM
$ACIU trimming staff, focused pipeline, good results with J&J. Do I smell something good cooking?
0 · Reply
leonp123
leonp123 Sep. 25 at 5:44 PM
$ACIU Something is moving here
0 · Reply
lucabrix
lucabrix Sep. 25 at 3:18 PM
$ACIU Reply!
0 · Reply
highnihilism
highnihilism Sep. 25 at 12:25 PM
Volume (Relative to 90-Day Average) → $ACIU Ac Immune × 1.8 $SHMD Schmid Group × 3.6 $BITF Bitfarms × 2.4 $YSXT YSX Tech × 4.6 $PSQH PSQ Holdings × 3
0 · Reply
EnzoDC
EnzoDC Sep. 25 at 11:43 AM
$ACIU ACI-35.030 looks very promising. This positive news can hopefully trigger short squeeze 📈📈📈
0 · Reply